+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Immunotherapy - Global Strategic Business Report

  • PDF Icon

    Report

  • 93 Pages
  • November 2023
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5303356

Quick Summary:

In the rapidly evolving landscape of pharmaceuticals and medicine, keeping pace with the latest trends and developments is crucial for strategic business decisions. Our recently published market research report on the Global Cancer Immunotherapy Market provides a comprehensive analysis and insights expected to be pivotal for business leaders and strategists.

Estimated at US$117.5 Billion in 2022, this market is projected to surge to US$378.5 Billion by 2030, with the Monoclonal Antibodies segment alone set to reach US$266.2 Billion. In the backdrop of a post-pandemic recovery, and the emergence of the Cancer Immunotherapy market as a key player in the U.S and China. This report also details competitive insights, with data on 42 featured companies including giants like AstraZeneca and Pfizer. Stay ahead of the curve by studying industry trends, regional market growth projections, pivotal competitors, and much more in our exclusive report.

Global Cancer Immunotherapy Market to Reach $378.5 Billion by 2030

The global market for Cancer Immunotherapy estimated at US$117.5 Billion in the year 2022, is projected to reach a revised size of US$378.5 Billion by 2030, growing at a CAGR of 15.7% over the analysis period 2022-2030. Monoclonal Antibodies, one of the segments analyzed in the report, is projected to record 16.8% CAGR and reach US$266.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Cytokines & Immunomodulators segment is readjusted to a revised 14.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $32 Billion, While China is Forecast to Grow at 21.5% CAGR

The Cancer Immunotherapy market in the U.S. is estimated at US$32 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$94 Billion by the year 2030 trailing a CAGR of 21.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.9% and 13.4% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11.6% CAGR.

Select Competitors (Total 42 Featured) -

  • Advaxis Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bayer AG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Immunomedics Inc.
  • Janssen Global Services, LLC (Johnson and Johnson)
  • Merck
  • Novartis
  • Pfizer
  • Seattle Genetics, Inc.
  • Spectrum Pharmaceuticals, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year
Frequently Asked Questions about the Global Market for Cancer Immunotherapy

What is the estimated value of the Global Market for Cancer Immunotherapy?

The Global Market for Cancer Immunotherapy was estimated to be valued at $117.5 Billion in 2022.

What is the growth rate of the Global Market for Cancer Immunotherapy?

The growth rate of the Global Market for Cancer Immunotherapy is 15.7%, with an estimated value of $378.5 Billion by 2030.

What is the forecasted size of the Global Market for Cancer Immunotherapy?

The Global Market for Cancer Immunotherapy is estimated to be worth $378.5 Billion by 2030.

Who are the key companies in the Global Market for Cancer Immunotherapy?

Key companies in the Global Market for Cancer Immunotherapy include Advaxis Inc., Amgen Inc., Astrazeneca, Bayer AG, Bristol, Myers Squibb, Celgene Corporation, ELI Lilly and Company, F. Hoffmann and La Roche Ltd.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Cancer Immunotherapy - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Cancer Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Cancer Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Cancer Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 13: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 14: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 15: World 16-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 16: World Recent Past, Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 17: World Historic Review for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 18: World 16-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 19: World Recent Past, Current & Future Analysis for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 20: World Historic Review for Prostate Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 21: World 16-Year Perspective for Prostate Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 22: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 23: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 24: World 16-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 25: World Recent Past, Current & Future Analysis for Head & Neck Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 26: World Historic Review for Head & Neck Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 27: World 16-Year Perspective for Head & Neck Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 28: World Cancer Immunotherapy Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 29: World Recent Past, Current & Future Analysis for Cytokines & Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 30: World Historic Review for Cytokines & Immunomodulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 31: World 16-Year Perspective for Cytokines & Immunomodulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
  • Table 33: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
  • Table 34: World 16-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
CANADA
JAPAN
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
CHINA
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
EUROPE
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
FRANCE
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
GERMANY
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
ITALY
UNITED KINGDOM
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
AUSTRALIA
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Cancer Immunotherapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Advaxis Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bayer AG
  • Bristol-Myers Squibb
  • Celgene Corporation
  • ELI Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Immunomedics Inc.
  • Janssen Global Services, LLC (Johnson and Johnson)
  • Merck
  • Novartis
  • Pfizer
  • Seattle Genetics, Inc.
  • Spectrum Pharmaceuticals, Inc.